All In Biotech

Drug Trial Radar · NCT07442071

Impact of Low Dose Epinephrine in the Management of Out-of-hospital Cardiac Arrest on Neurological Outcome

Impact of Low Dose Epinephrine in the Management of Out-of-hospital Cardiac Arrest on Neurological Outcome: A Multicenter Randomized and Double-blind Trial.

Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 4,336 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

4,336

Planned (sponsor's estimate)

Start

Jun 2026

Primary completion

Jul 2030

Study completion Jul 2030

Sponsor

Lead sponsor
Central Hospital, Nancy, FranceAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will test whether a lower dose of epinephrine (0.5 mg) given during emergency treatment for out-of-hospital cardiac arrest helps more patients survive with good brain function, compared to the standard dose (1 mg). Adults who experience cardiac arrest outside the hospital and are treated by emergency medical teams will be randomly assigned to receive either the low dose or the standard dose of epinephrine. The study will compare survival and neurological outcomes between the two groups over 28 days.

Conditions

  • Out-of-hospital Cardiac Arrest (OHCA)

Interventions

  • Epinephrine 0.5 mg intravenous bolusDrug

    Epinephrine 0.5 mg/mL solution for injection, administered as a 0.5 mg intravenous bolus every 3 to 5 minutes during cardiopulmonary resuscitation (CPR) for out-of-hospital cardiac arrest. T

  • Epinephrine 1 mg intravenous bolusDrug

    Epinephrine 1 mg/mL solution for injection, administered as a 1 mg intravenous bolus every 3 to 5 minutes during cardiopulmonary resuscitation (CPR) for out-of-hospital cardiac arrest.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Modified Rankin Scale (mRS) scoreTime frame: 28-day

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • CH Annecy

    Annecy, France

  • Centre hospitalier de la Côte Basque

    Bayonne, France

  • CHU Besancon

    Besançon, France

  • CHU Brest

    Brest, France

  • CHU Colmar

    Colmar, France

  • CH SUD Francilien

    Corbeil-Essonnes, France

  • Brigade de Sapeurs-Pompiers de Paris

    Courbevoie, France

  • Centre Hospitalier Universitaire Grenoble Alpes

    La Tronche, France

  • Hospices Civils De Lyon

    Lyon, France

  • CHU Montpellier

    Montpellier, France

  • CHRU Nancy

    Nancy, France

  • Centre Hospitalier Universitaire De Nantes

    Nantes, France

  • CHU Nice

    Nice, France

  • CHU Nimes

    Nîmes, France

  • AP-HP Hôpital Necker

    Paris, France

  • Hopital Beaujon

    Paris, France

  • hôpital Lariboisière

    Paris, France

  • La Pitié Salpêtrière

    Paris, France

  • Raymond Poincaré Hospital

    Paris, France

  • CHU Poitiers

    Poitiers, France

  • Centre Hospitalier Universitaire Reims

    Reims, France

  • CHU Rennes

    Rennes, France

  • CHU Rouen

    Rouen, France

  • Centre hospitalier Annecy Genevois Site Julien en GENEVOIS

    Saint-Julien-en-Genevois, France

  • Centre Hospitalier Universitaire De Toulouse

    Toulouse, France

  • CHU Tours

    Tours, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.